Instead, we represented the distribution of differential enrichments (y) for all mACPs tested against each cancer cell line (x), as illustrated in Figures and. Several cancer cell lines presented a similar or identical distribution of peptides within a specific range of differential enrichments. For example, the breast cancer cell line MDA-MB-361 displayed the narrowest ranges of differential enrichments where the tested mACPs were predominantly cationic (0.35 to 0.50, Figure ) and hydrophobic (-0.10 to -0.50, Figure ). In contrast, the brain cancer cell line named U251-MG was used against the broadest range of peptides. Nevertheless, both sets of mACPs inhibited these cancer cell lines with the same order of magnitude, i.e., pIC50 values ranging from 4.0 to 5.6 (Figures and). We measured the goodness of fit between all CCL distributions using the two-sample Kolmogorov-Smirnov test, considering the different mACP sample sizes. The results are summarised in Figures and. Both figures indicated that cancer cell lines U251-MG, NCI-H157, and PC-3 formed one strong cluster. Likewise, the cancer cell lines HeLa S3, SW480, and CCRF-CEM adopted identical or similar distributions, whereas blood CCLs Jurkat E6-1 and K562 fitted moderately. We hypothesised that the cancer cell lines with similar or identical distributions were tested either (1) against the same set / homologous mACPs or (2) that these cell lines would consist of similar membrane lipid compositions akin to mACPs with preferential amino acid composition. Regarding the first hypothesis, we evaluated the proportions of matching mACPs across the 11 CCLs. High goodness of fit between cancer cell lines resulted from identical peptide sequences (Table ). The same twenty-five mACPs inhibited the cancer cell lines HeLa S3, SW480, and CCRF-CEM. A minimum of 15 common peptides exhibited anticancer activity against U251-MG, NCI-H157, and PC-3. Finally, Jurkat E6-1 and K562 cell lines were tested simultaneously using twenty-seven mACPs. In that last example, both cell lines responded similarly to the peptides, as illustrated by individual pIC50 values in Figures and, suggesting similar membrane lipid compositions. Both cell lines belong to blood cancer. In contrast, the peptides tested against HeLa S3, SW480, and CCRF-CEM or U251-MG, NCI-H157, and PC-3 showed different individual pIC50 values. These cell lines belong to different cancer types and may present distinct membrane lipid types or compositions. We curated lipidomic studies over some of these cancer cell lines (i.e., HL-60, K562, SW480, A549, PC-3) comparing their contents in phospholipids or fatty acids, see Supporting Information Lipid_composition_CCLs.xlsx. Our analyses did not support nor reject the second hypothesis.